ASAna C. Vicente Santos

Ana C. Vicente Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana C. Vicente Santos has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Andre Marco Oliveira Gomes

    Institute of Medical Biochemistry Leopoldo de Meis and National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, RJ, Brazil

    2 shared publications
  • Andrea Oliveira

    Departamento de Química, Universidade Federal do Paraná, Curitiba CEP 81531-980, PR, Brazil

    2 shared publications
  • Herbert Leonel de Matos Guedes

    Immunobiotechnology Laboratory, Institute of Microbiology Paulo de Góes, Federal University of Rio de Janeiro

    2 shared publications
  • Jerson Lima Silva

    National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil

    2 shared publications
  • Alessandra Almeida Filardy

    Programa de Pós-Graduação em Ciências (Microbiologia), Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Brazil; Laboratório de Imunologia Celular, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Brazil; Programa de Pós-Graduação em Ciências (Microbiologia), Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Brazil

    1 shared publication
  • Alessandra Marcia da Fonseca-Martins

    Instituto de Microbiologia Professor Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

    1 shared publication

Latest Publications

  • Open Access

    Yellow fever vaccine protects mice against Zika virus infection

    by Ana C. Vicente Santos, Francisca H. Guedes-Da-Silva, Carlos H. Dumard, Vivian N. S. Ferreira, Igor P. S. da Costa, Ruana A. Machado, Fernanda G. Q. Barros-Aragão, Rômulo L. S. Neris, Júlio S. Dos-Santos, Iranaia Assunção-Miranda, et al.

    Zika virus (ZIKV) emerged as an important infectious disease agent in Brazil in 2016. Infection usually leads to mild symptoms, but severe congenital neurological disorders and Guillain-Barré syndrome have been reported following ZIKV exposure. Creating an effective vaccine against ZIKV is a public health priority. We describe the protective effect of an already licensed attenuated yellow fever vaccine (YFV, 17DD) in type-I interferon receptor knockout mice (A129) and immunocompetent BALB/c and SV-129 (A129 background) mice infected with ZIKV. YFV vaccination provided protection against ZIKV, with decreased mortality in A129 mice, a reduction in the cerebral viral load in all mice, and weight loss prevention in BALB/c mice. The A129 mice that were challenged two and three weeks after the first dose of the vaccine were fully protected, whereas partial protection was observed five weeks after vaccination. In all cases, the YFV vaccine provoked a substantial decrease in the cerebral viral load. YFV immunization also prevented hippocampal synapse loss and microgliosis in ZIKV-infected mice. Our vaccine model is T cell-dependent, with AG129 mice being unable to tolerate immunization (vaccination is lethal in this mouse model), indicating the importance of IFN-γ in immunogenicity. To confirm the role of T cells, we immunized nude mice that we demonstrated to be very susceptible to infection. Immunization with YFV and challenge 7 days after booster did not protect nude mice in terms of weight loss and showed partial protection in the survival curve. When we evaluated the humoral response, the vaccine elicited significant antibody titers against ZIKV; however, it showed no neutralizing activity in vitro and in vivo. The data indicate that a cell-mediated response promotes protection against cerebral infection, which is crucial to vaccine protection, and it appears to not necessarily require a humoral response. This protective effect can also be attributed to innate factors, but more studies are needed to strengthen this hypothesis. Our findings open the way to using an available and inexpensive vaccine for large-scale immunization in the event of a ZIKV outbreak.


  • Open Access

    Immunogenicity of SARS-CoV-2 trimetric spike protein associated to Poly(I:C) plus Alum

    by Júlio Souza Dos-Santos, Luan Firmino-Cruz, Alessandra Marcia da Fonseca-Martins, Diogo Oliveira-Maciel, Gustavo Guadagini Perez, Victor A. R. Pereira, Carlos H. Dumard, Francisca H. Guedes-Da-Silva, Ana C. Vicente Santos, Monique dos Santos Leandro, et al.

    The SARS-CoV-2 pandemic has had a social and economic impact worldwide, and vaccination is an efficient strategy for diminishing those damages. New adjuvant formulations are required for the high vaccine demands, especially adjuvant formulations that induce a Th1 phenotype. Herein we assess a vaccination strategy using a combination of Alum and polyinosinic:polycytidylic acid (Poly(I:C)) adjuvants plus the SARS-CoV-2 spike protein in a prefusion trimeric conformation by an intradermal (ID) route. We found high levels of IgG anti-spike antibodies in the serum by enzyme linked immunosorbent assay (ELISA) and high neutralizing titers against SARS-CoV-2 in vitro by neutralization assay, after one or two boosts. By evaluating the production of IgG subtypes, as expected, we found that formulations containing Poly(I:C) induced IgG2a whereas Alum did not. The combination of these two adjuvants induced high levels of both IgG1 and IgG2a. In addition, cellular immune responses of CD4 + and CD8 + T cells producing interferon-gamma were equivalent, demonstrating that the Alum + Poly(I:C) combination supported a Th1 profile. Based on the high neutralizing titers, we evaluated B cells in the germinal centers, which are specific for receptor-binding domain (RBD) and spike, and observed that more positive B cells were induced upon the Alum + Poly(I:C) combination. Moreover, these B cells produced antibodies against both RBD and non-RBD sites. We also studied the impact of this vaccination preparation (spike protein with Alum + Poly(I:C)) in the lungs of mice challenged with inactivated SARS-CoV-2 virus. We found a production of IgG, but not IgA, and a reduction in neutrophil recruitment in the bronchoalveolar lavage fluid (BALF) of mice, suggesting that our immunization scheme reduced lung inflammation. Altogether, our data suggest that Alum and Poly(I:C) together is a possible adjuvant combination for vaccines against SARS-CoV-2 by the intradermal route.